Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Addressing Barriers to Diagnosis and Genetic Testing for Duchenne Muscular Dystrophy, Potential Extramural Projects (PEP) 2008-R-12, 21630 [E8-8643]

Download as PDF 21630 Federal Register / Vol. 73, No. 78 / Tuesday, April 22, 2008 / Notices 3. North Star Holding Company, Inc., Jamestown, North Dakota; to acquire 100 percent of the voting shares of Unison Bank, Mesa, Arizona (a de novo bank). 4. Wishek Bancorporation, Inc., Wishek, North Dakota; to acquire through its 28.26 percent ownership of North Star Holding Company, Inc., Jamestown, North Dakota, shares of Unison Bank, Mesa, Arizona (a de novo bank). Board of Governors of the Federal Reserve System, April 17, 2008. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. E8–8666 Filed 4–21–08; 8:45 am] BILLING CODE 6210–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Development of Herpes Simplex Virus (HSV)–2 Serologic Testing Algorithms, Potential Extramural Projects (PEP) 2008–R–21 sroberts on PROD1PC70 with NOTICES In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting. Time and Date: 1 p.m.–2 p.m., May 14, 2008 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters to be Discussed: The meeting will include the review, discussion, and evaluation of ‘‘Development of Herpes Simplex Virus (HSV)–2 Serologic Testing Algorithms, PEP 2008–R–21.’’ Contact Person for More Information: Linda Shelton, Program Specialist, Coordinating Center for Health and Information Service, Office of the Director, CDC, 1600 Clifton Road, NE., Mailstop E21, Atlanta, GA 30333, Telephone (404)498– 1194. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. VerDate Aug<31>2005 16:25 Apr 21, 2008 Jkt 214001 Dated: April 15, 2008. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E8–8616 Filed 4–21–08; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: April 15, 2008. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E8–8617 Filed 4–21–08; 8:45 am] Centers for Disease Control and Prevention BILLING CODE 4163–18–P Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Evaluation of the Validity of Coverage Survey SelfReported Audit Vaccination Status, Funding Opportunity Announcement (FOA) IP08–003; Strategies to Extend the Influenza Vaccination Season in Medical Practices, IP08–004; Effectiveness of a Hospital-Based Program for Vaccination of Birth Mothers and Household Contacts with Influenza Vaccines and Combined Tetanus Toxoid and a Cellular Pertussis Vaccine, FOA IP08–005; Effectiveness of an Intervention to Promote a Targeted Vaccination Program in the ObstetricianGynecologist Setting, FOA IP08–008 DEPARTMENT OF HEALTH AND HUMAN SERVICES In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting: Time and Date: 1 p.m.–2 p.m., May 16, 2008 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters to be Discussed: The meeting will include the review, discussion, and evaluation of ‘‘Addressing Barriers to Diagnosis and Genetic Testing for Duchenne Muscular Dystrophy, PEP 2008–R–12.’’ Contact Person for More Information: Linda Shelton, Program Specialist, Coordinating Center for Health and Information Service, Office of the Director, CDC, 1600 Clifton Road, NE., Mailstop E21, Atlanta, GA 30333, Telephone (404) 498– 1194. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Time and Date: 12 p.m.–4 p.m., May 20, 2008 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters to be Discussed: The meeting will include the review, discussion, and evaluation of ‘‘Evaluation of the Validity of Coverage Survey Self-Reported Audit Vaccination Status, FOA IP08–003; Strategies to Extend the Influenza Vaccination Season in Medical Practices, FOA IP08–004; Effectiveness of a Hospital-Based Program for Vaccination of Birth Mothers and Household Contacts with Influenza Vaccines and Combined Tetanus Toxoid and a Cellular Pertussis Vaccine, FOA IP08–005; Effectiveness of an Intervention to Promote a Targeted Vaccination Program in the Obstetrician-Gynecologist Setting, FOA IP08– 008.’’ Contact Person for More Information: Sheree Marshall Williams, Ph.D., Scientific Review Administrator, CDC, 1600 Clifton Road, NE., Mailstop D72, Atlanta, GA 30333, Telephone: (404) 639–4896. The Director, Management Analysis and Services Office, has been delegated the PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Addressing Barriers to Diagnosis and Genetic Testing for Duchenne Muscular Dystrophy, Potential Extramural Projects (PEP) 2008–R–12 In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting. Dated: April 15, 2008. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E8–8643 Filed 4–21–08; 8:45 am] BILLING CODE 4163–18–P E:\FR\FM\22APN1.SGM 22APN1

Agencies

[Federal Register Volume 73, Number 78 (Tuesday, April 22, 2008)]
[Notices]
[Page 21630]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-8643]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP): Addressing Barriers to Diagnosis and Genetic 
Testing for Duchenne Muscular Dystrophy, Potential Extramural Projects 
(PEP) 2008-R-12

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the aforementioned meeting.

    Time and Date: 1 p.m.-2 p.m., May 16, 2008 (Closed).
    Place: Teleconference.
    Status: The meeting will be closed to the public in accordance 
with provisions set forth in section 552b(c)(4) and (6), Title 5 
U.S.C., and the Determination of the Director, Management Analysis 
and Services Office, CDC, pursuant to Public Law 92-463.
    Matters to be Discussed: The meeting will include the review, 
discussion, and evaluation of ``Addressing Barriers to Diagnosis and 
Genetic Testing for Duchenne Muscular Dystrophy, PEP 2008-R-12.''
    Contact Person for More Information: Linda Shelton, Program 
Specialist, Coordinating Center for Health and Information Service, 
Office of the Director, CDC, 1600 Clifton Road, NE., Mailstop E21, 
Atlanta, GA 30333, Telephone (404) 498-1194.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining 
to announcements of meetings and other committee management 
activities, for both CDC and the Agency for Toxic Substances and 
Disease Registry.

    Dated: April 15, 2008.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. E8-8643 Filed 4-21-08; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.